|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients显示文摘AIM:To analyze whether high-intensity focused ultrasound(HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma(HCC).METHODS:From January 2007 to December 2010,49 consecutive HCC patients were listed for liver transplantation(UCSF criteria).The median waiting time for transplantation was 9.5 mo.Twenty-nine patients received transarterial chemoembolization(TACE) as a bringing therapy and 16 patients received no treatment before transplantation.Five patients received HIFU ablation as a bridging therapy.Another five patients with the same tumor staging(within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison.Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores,tumor size and number,and cause of cirrhosis.RESULTS:The HIFU group and TACE group showed no difference in terms of tumor size and tumor number.One patient in the HIFU group and no patient in the TACE group had gross ascites.The median hospital stay was 1 d(range,1-21 d) in the TACE group and two days(range,1-9 d) in the HIFU group(P < 0.000).No HIFU-related complication occurred.In the HIFU group,nine patients(90%) had complete response and one patient(10%) had partial response to the treatment.In the TACE group,only one patient(3%) had response to the treatment while 14 patients(48%) had stable disease and 14 patients(48%) had progressive disease(P = 0.00).Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list(P = 0.559).CONCLUSION:HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis.It may reduce the drop-out rate of liver transplant candidate. | Tan To Cheung Sheung Tat Fan See Ching Chan Kenneth SH Chok Ferdinand SK Chu Caroline R Jenkins Regina CL Lo James YY Fung Albert CY Chan William W Sharr Simon HY Tsang Wing Chiu Dai Ronnie TP Poon Chung Mau Lo | 2013 | World Journal of Gastroenterology2013，19，20： | 23 |
| 2 | Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects显示文摘 | Ciaraldi TP Kong AP Chu NV | 2002 | Diabetes2002，51，1： | 1 |
| 3 | Regulation of glu-cose transport and insulin signaling by troglitazone or met-formin in adipose tissue of type 2 diabetic subjects显示文摘 | Ciaraldi TP Kong AP Chu NV | 2002 | Dia-betes2002，51，1： | 1 |
| 4 | Expression, purification, and characterization of protective MPT64 antigen protein and identification of its multimers isolated from nontoxic Mycobacterium tuberculosis H37Ra 显示文摘 | Chu TP Yuann JM | 2011 | Biotechnol Appl Biochem2011，58，3： | 1 |
| 5 | Geographical variations in Wilsonr s disease显示文摘 | Chu NS Haung TP | 1993 | J Neurol Sci1993，117，6： | 1 |
| 6 | Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects显示文摘 | Ciaraldi TP Kong AP Chu NV | 2002 | Diabetes2002，51，1： | 1 |
| 7 | Prospective evaluation of selective defunctioning stoma for low anterior resection with total mesorectal excision 显示文摘 | Chu K Ho JW | 1999 | World J Surg1999，23，： | 1 |
| 8 | Expression, purification, and characterization of protective MPT64 antigen protein and identification of its multimers isolated from nontoxic Mycobacterium tuberculosis H37Ra显示文摘 | Chu TP Yuann JM | 2011 | Biotechnol App1Biochem2011，58，3： | 1 |
| 9 | Radiation therapy of cancer in prosthetically augmented or reconstructed breasts显示文摘 | Chu FC Kaufmann TP Dawson GA | 1992 | Radiology1992，185，2： | 1 |
| 10 | Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects显示文摘 | Ciaraldi TP Kong AP Chu NV | | 0，，： | 1 |
| 11 | Prevalence of acid- reducing agents (ARA) in cancer populations and ARA drug- drug interaction potential for molecular targeted agents in clinical development显示文摘 | Smelick GS Heffron TP Chu L | 2013 | Mol Pharm2013，10，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员